With SAJAZIR (icatibant), hereditary angioedema (HAE) treatment1 is within easy reach*
*SAJAZIR injection is a prefilled syringe for subcutaneous use.1 Patients should not inject SAJAZIR until they have been trained by a Cycle Vita product support nurse or their healthcare provider.
SAJAZIR is an FDA-approved injection indicated for the treatment of acute attacks of HAE in adults aged 18 years and older.1,2
So why choose SAJAZIR?1
SAJAZIR is an accessible, portable prefilled icatibant injection accompanied by broad product support, helping you have a seamless experience, from enrollment to treatment initiation and beyond.
Discuss with your healthcare provider if SAJAZIR is right for you.
Effective symptom reduction for HAE attacks,1 within easy reach*
SAJAZIR comes in the form of a convenient, portable, prefilled injection that you will be trained to self-administer subcutaneously as soon as you notice the signs of an HAE attack coming on.
SAJAZIR can be used to treat acute HAE attacks, including skin (cutaneous), stomach (abdominal), and throat (laryngeal).
In three clinical trials, icatibant has been shown in select patients to:1
Reduce symptoms by 50% in around 2 hours, with results ranging between 1.5–3 hours, even after multiple attacks (vs. almost 20 hours with placebo, in non-throat attacks) in one clinical trial with 43 patients
Achieve almost complete symptom relief in around 8 hours, with results ranging between 5.0 and 42.5 hours (vs. 36 hours with placebo) in one clinical trial with 43 patients
Treat 9 out of 10 attacks (93%) with a single dose in three clinical trials with 225 patients
It’s important to remember that HAE attacks of the throat (laryngeal attacks) can become life threatening—if you have a laryngeal attack, inject SAJAZIR and then go to the nearest hospital emergency room right away.
Start your SAJAZIR enrollment here
Download, complete and fax a PDF
References
- SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.
- FDA. FDA-approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212446 (accessed October 2021).